Yin-chun Ji

发表

Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.

Youhong Hu, M. Geng, Dong Lu, 2017, ACS medicinal chemistry letters.

Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.

Youhong Hu, M. Geng, Dong Lu, 2015, European journal of medicinal chemistry.

Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold.

Wei Zhang, M. Geng, Yingxia Li, 2016, Bioorganic & medicinal chemistry letters.

Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.

M. Geng, Jian-Ping Lin, Yong Wang, 2013, Organic & biomolecular chemistry.

Discovery of novel type II c-Met inhibitors based on BMS-777607.

Wei Zhang, M. Geng, Yingxia Li, 2014, European journal of medicinal chemistry.

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation

Yi Chen, Youhong Hu, Yan-fen Fang, 2021, Molecular Cancer Therapeutics.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of Experimental & Clinical Cancer Research.

Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase.

Qiu-feng Liu, H. Su, Yin-chun Ji, 2022, Journal of medicinal chemistry.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Hualiang Jiang, Hong Liu, Zhongjie Liang, 2012, Bioorganic & medicinal chemistry.

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Yechun Xu, M. Geng, Qiu-feng Liu, 2012, Bioorganic & medicinal chemistry letters.

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.

Yechun Xu, M. Geng, Qiu-feng Liu, 2016, European journal of medicinal chemistry.

Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.

M. Geng, Hongchun Liu, Yin-chun Ji, 2017, Bioorganic & medicinal chemistry letters.

Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.

Jian Ding, M. Geng, B. Xiong, 2015, Journal of medicinal chemistry.

Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.

M. Geng, Yin-chun Ji, Zilan Song, 2018, European journal of medicinal chemistry.

Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.

Yi Chen, M. Geng, Yin-chun Ji, 2014, ACS medicinal chemistry letters.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of experimental & clinical cancer research : CR.

Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors

Dong-mei Zhao, M. Geng, B. Xiong, 2016, Acta Pharmacologica Sinica.

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

Jian Ding, Yin-chun Ji, W. Duan, 2020, Acta Pharmacologica Sinica.

SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET–Dependent Neoplastic Effects and Exerts Antitumor Activity

Min Huang, Yi Chen, Jian Ding, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.

M. Geng, Yin-chun Ji, Qizheng Yao, 2015, Bioorganic & medicinal chemistry.

An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.

M. Geng, Yin-chun Ji, L. Xing, 2016, European journal of medicinal chemistry.

Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Jian Ding, M. Geng, Yin-chun Ji, 2014, European journal of medicinal chemistry.

Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

Xutong Li, M. Geng, Hong Liu, 2023, Journal of medicinal chemistry.

Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity.

Yechun Xu, M. Geng, Qiu-feng Liu, 2014, ACS medicinal chemistry letters.

Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core.

Yin-chun Ji, L. Xing, Zilan Song, 2019, Bioorganic & medicinal chemistry letters.

Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.

M. Geng, Yin-chun Ji, W. Duan, 2021, European journal of medicinal chemistry.

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.

Weiliang Zhu, Hualiang Jiang, Hong Liu, 2013, Bioorganic & medicinal chemistry letters.

Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.

M. Geng, Yin-chun Ji, L. Xing, 2016, Bioorganic & medicinal chemistry letters.

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Liang Liu, Yin-chun Ji, E. Leung, 2017, MedChemComm.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Wei-ren Liu, 2016, Oncotarget.

neoplastic effects and exerts antitumor activity

Yi Chen, Jian Ding, M. Geng, 2014 .

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Yi Chen, Jian Ding, M. Geng, 2017, Molecular Cancer Therapeutics.

Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition

Yi Chen, M. Geng, Zhaobing Gao, 2012 .

Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis

Yi Zang, B. Xiong, Jia Li, 2021, Acta pharmaceutica Sinica. B.

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.

M. Geng, B. Xiong, Yuchen Jiang, 2019, European journal of medicinal chemistry.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta pharmacologica Sinica.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta Pharmacologica Sinica.

Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold

Wei Zhang, M. Geng, Yin-chun Ji, 2014, Molecules.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Yin-chun Ji, 2016, Oncotarget.

Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.

X. Chen, Hong Liu, M. Geng, 2015, ACS medicinal chemistry letters.

Synthesis of triazolotriazine derivatives as c-Met inhibitors

Jian Ding, Yin-chun Ji, W. Duan, 2020, Molecular Diversity.

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors

Yu Zhou, Chunpu Li, Yin-chun Ji, 2023, Acta pharmaceutica Sinica. B.